Literature DB >> 22531980

Retinoids ameliorate insulin resistance in a leptin-dependent manner in mice.

Hiroyuki Tsuchiya1, Yoshito Ikeda, Yu Ebata, Chihiro Kojima, Rikutaro Katsuma, Tatsuaki Tsuruyama, Tomohiko Sakabe, Kohei Shomori, Noriko Komeda, Shoko Oshiro, Hideharu Okamoto, Kazuko Takubo, Susumu Hama, Koichi Shudo, Kentaro Kogure, Goshi Shiota.   

Abstract

UNLABELLED: Transgenic mice expressing dominant-negative retinoic acid receptor (RAR) α specifically in the liver exhibit steatohepatitis, which leads to the development of liver tumors. Although the cause of steatohepatitis in these mice is unknown, diminished hepatic expression of insulin-like growth factor-1 suggests that insulin resistance may be involved. In the present study, we examined the effects of retinoids on insulin resistance in mice to gain further insight into the mechanisms responsible for this condition. Dietary administration of all-trans-retinoic acid (ATRA) significantly improved insulin sensitivity in C57BL/6J mice, which served as a model for high-fat, high-fructose diet-induced nonalcoholic fatty liver disease (NAFLD). The same effect was observed in genetically insulin-resistant KK-A(y) mice, occurring in concert with activation of leptin-signaling pathway proteins, including signal transducer and activator of transcription 3 (STAT3) and Janus kinase 2. However, such an effect was not observed in leptin-deficient ob/ob mice. ATRA treatment significantly up-regulated leptin receptor (LEPR) expression in the livers of NAFLD mice. In agreement with these observations, in vitro experiments showed that in the presence of leptin, ATRA directly induced LEPR gene expression through RARα, resulting in enhancement of STAT3 and insulin-induced insulin receptor substrate 1 phosphorylation. A selective RARα/β agonist, Am80, also enhanced hepatic LEPR expression and STAT3 phosphorylation and ameliorated insulin resistance in KK-A(y) mice.
CONCLUSION: We discovered an unrecognized mechanism of retinoid action for the activation of hepatic leptin signaling, which resulted in enhanced insulin sensitivity in two mouse models of insulin resistance. Our data suggest that retinoids might have potential for treating NAFLD associated with insulin resistance.
Copyright © 2012 American Association for the Study of Liver Diseases.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22531980     DOI: 10.1002/hep.25798

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  23 in total

Review 1.  Retinoid roles in blocking hepatocellular carcinoma.

Authors:  Yohei Shirakami; Hiroyasu Sakai; Masahito Shimizu
Journal:  Hepatobiliary Surg Nutr       Date:  2015-08       Impact factor: 7.293

2.  Retinoic acid receptor β stimulates hepatic induction of fibroblast growth factor 21 to promote fatty acid oxidation and control whole-body energy homeostasis in mice.

Authors:  Yu Li; Kimberly Wong; Kenneth Walsh; Bin Gao; Mengwei Zang
Journal:  J Biol Chem       Date:  2013-02-19       Impact factor: 5.157

Review 3.  Asthma and metabolic syndrome: Current knowledge and future perspectives.

Authors:  Laura Serafino-Agrusa; Mario Spatafora; Nicola Scichilone
Journal:  World J Clin Cases       Date:  2015-03-16       Impact factor: 1.337

4.  Retinoic acid receptor β2 agonists restore glycaemic control in diabetes and reduce steatosis.

Authors:  S E Trasino; X-H Tang; J Jessurun; L J Gudas
Journal:  Diabetes Obes Metab       Date:  2015-12-23       Impact factor: 6.577

5.  17-Beta Hydroxysteroid Dehydrogenase 13 Is a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease.

Authors:  Yanling Ma; Olga V Belyaeva; Philip M Brown; Koji Fujita; Katherine Valles; Suman Karki; Ynto S de Boer; Christopher Koh; Yanhua Chen; Xiaomeng Du; Samuel K Handelman; Vincent Chen; Elizabeth K Speliotes; Cara Nestlerode; Emmanuel Thomas; David E Kleiner; Joseph M Zmuda; Arun J Sanyal; Natalia Y Kedishvili; T Jake Liang; Yaron Rotman
Journal:  Hepatology       Date:  2019-03-05       Impact factor: 17.425

6.  Pharmacological agents for nonalcoholic steatohepatitis.

Authors:  Maeva Guillaume; Vlad Ratziu
Journal:  Hepatol Int       Date:  2013-11-19       Impact factor: 6.047

7.  Xanthophyll β-cryptoxanthin treatment inhibits hepatic steatosis without altering vitamin A status in β-carotene 9',10'-oxygenase knockout mice.

Authors:  Chun Liu; Bruna Paola M Rafacho; Xiang-Dong Wang
Journal:  Hepatobiliary Surg Nutr       Date:  2022-04       Impact factor: 7.293

8.  Krüppel-like factor 2 promotes liver steatosis through upregulation of CD36.

Authors:  Jin-Lian Chen; Xiao-Jie Lu; Kai-Lin Zou; Kun Ye
Journal:  J Lipid Res       Date:  2013-07-15       Impact factor: 5.922

9.  All-trans-retinoic acid ameliorates hepatic steatosis in mice by a novel transcriptional cascade.

Authors:  Seong Chul Kim; Chun-Ki Kim; David Axe; Aaron Cook; Mikang Lee; Tiangang Li; Nicole Smallwood; John Y L Chiang; James P Hardwick; David D Moore; Yoon Kwang Lee
Journal:  Hepatology       Date:  2014-03-26       Impact factor: 17.425

10.  Alcohol dehydrogenase III exacerbates liver fibrosis by enhancing stellate cell activation and suppressing natural killer cells in mice.

Authors:  Hyon-Seung Yi; Young-Sun Lee; Jin-Seok Byun; Wonhyo Seo; Jong-Min Jeong; Ogyi Park; Gregg Duester; Takeshi Haseba; Sun Chang Kim; Keun-Gyu Park; Bin Gao; Won-Il Jeong
Journal:  Hepatology       Date:  2014-05-09       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.